【摘要】 目的 探讨分析安罗替尼联合CAPEOX/mFOLFOX6方案一线治疗晚期结直肠癌的临床研究。方法 选择2021年4月～2023年10月鄂尔多斯市中心医院接受治疗的50例晚期结直肠癌患者，随机分为对照组（接受CAPEOX/mFOLFOX6方案一线治疗）与观察组（接受安罗替尼联合CAPEOX/mFOLFOX6方案一线治疗），各25例，对研究完成后结果进行比较与分析。结果 观察组近期有效率高于对照组（P <0.05）。治疗后，观察组Karnofsky功能状态（KPS）评分高于对照组，对照组美国东部肿瘤协会组体力状况评分（ZPS）评分高于观察组，差异有统计学意义（P <0.05）。两组不良反应发生率相比差异无统计学意义（P> 0.05）。治疗前两组患者的VEGF、TGF-β水平比较差异无统计学意义（P> 0.05），治疗后对照组内皮生长因子（VEGF）、转化生长因子β(TGF-β)水平高于观察组，差异有统计学意义（P <0.05）。治疗前两组患者的T淋巴细胞亚群水平比较差异无统计学意义（P> 0.05），治疗后观察组CD4~+、CD8~+以及CD4~+/CD8~+水平高于对照组，差异有统计学意义（P <0.05）。结论 安罗替尼联合CAPEOX/mFOLFOX6方案一线治疗晚期结直肠癌患者疗效确切，不良反应可控，对患者的生活质量能够产生一定的改善效果。更多还原

【Abstract】 Objective To explore and analyze the clinical study of the combination of anlotinib and CAPEOX/mFOLFOX6 regimen for first-line treatment of advanced colorectal cancer. Methods Fifty patients with advanced colorectal cancer who received treatment in Ordos City Central Hospital from April 2021 to October 2023 were randomly divided into the control group(receiving first-line treatment with CAPEOX/mFOLFOX6regimen) and the observation group(receiving first-line treatment with anlotinib combined with CAPEOX/mFOLFOX6 regimen) with 25 cases in each group. The results after the completion of the study were compared and analyzed.Results The short-term effective rate of the observation group was higher than that of the control group(P < 0.05).KPS score of the observation group was higher than the control group after treatment, ZPS score of the control group was higher than that of the observation group, with significant difference(P < 0.05). There was no difference in the incidence of adverse reactions between the two groups(P > 0.05).There was no significant difference in the levels of VEGF and TGF-β between the two groups before treatment(P > 0.05), while the levels of VEGF and TGF-β in the control group were higher than those in the observation group after treatment, and the difference was statistically significant(P < 0.05). There was no significant difference in the levels of T lymphocyte subsets between the two groups before treatment(P > 0.05), while the levels of CD4~+, CD8~+, and CD4~+/CD8~+ in the observation group were higher than those in the control group after treatment, and the difference was statistically significant(P < 0.05). Conclusion Anlotinib combined with CAPEOX/mFOLFOX6 is effective in the first-line treatment of advanced colorectal cancer patients, and the adverse reactions can be controlled, and the amount of life of patients can be improved to some extent.更多还原